Management of Cesarean Scar Pregnancy: A Single-Institution Retrospective Review

Table 1

Clinical patient’s data in relation to treatment modality.

	EM	HSC	MTX ii and D&S	UAE and D&S	UAE and Surg.	-value
Gestational age (wks)	6 ± 0,82	6,8 ± 0,84	7,21 ± 0,63	8,0 ± 1,73	10,17 ± 1,17	≤0.001
Women age (y)	34,5 ± 3,11	32,6 ± 4,93	32,68 ± 3,92	34,55 ± 2,62	35,67 ± 1,75	0.31
previous CDs (no.)	1,25 ± 0,50	1,4 ± 0,55	1,68 ± 0,58	2,64 ± 0,71	3,5 ± 0,55	≤0.001
Myometrial thickness (mm)	3,78 ± 0,33	3,36 ± 0,35	3,07 ± 0,63	1,96 ± 0,99	1,08 ± 0.50	≤0.001
Rich vascular pattern	0	0	19 (100)	11 (100)	6 (100)	≤0.001
BhCG (mIU/mL)	5890,5 ± 1284,15	9756 ± 3286,50	11790 ± 4904,67	49976,54 ± 686636,34	16909,83 ± 48712,1	≤0.001
Complication	1 (25)	0	0	9 (81,8)	0	≤0.001

EM: expectant management; HSC: hysteroscopic resection; MTH ii: methotrexate intramuscular injection; D&S: dilatation and suction; UAE: uterine artery embolization; Surg: surgery. are shown as mean ± SD; statistical analysis performed by one-way analysis of variance. are shown as no. (percentage); statistical analysis performed by test.